COVID-19 Vaccines: Moderna, Pfizer/BioNTech, AstraZeneca/Oxford

More than 150 COVID-19 vaccines are in development around the world. The hope is that at least one of these could be brought to market quickly, something that could ease the global crisis in which we now find ourselves. The U.S. government has launched Operation Warp Speed, pledging $10 billion to developing, testing, and distributing […]

A Look at Moderna’s SARS-CoV-2 Vaccine

Moderna’s recent announcement of interim results from the ongoing clinical trial on its vaccine candidate, mRNA-1273, reveals data promising enough for the phase 1 study to move forward to the next phase. The study was designed to determine the safety of the vaccine while examining the immunogenicity at various doses. Despite the small number of […]

The Cast Is Coming Off for the Orthopedics Field to Make a Full Recovery

Most medical practices would’ve seen a relatively normal, solid performance in the first quarter. But things shifted dramatically in April, as each state, particularly in the Northeast, started to restrict elective surgery and patients grew concerned. Hospitals were overwhelmed with admissions and started to repurpose operating rooms. This all had a halting effect on the […]

Dermatology’s COVID-19 Problems Are Deep and Will Take Time to Heal

Dermatology practices were generally coming off a strong year and poised for another robust performance in 2020. All four dermatology sectors – medical, surgical, dermatopathology, and cosmetic – exhibited impressive patient activity for the first 10 weeks of this new year. Merger and acquisition activity was also moving at a brisk pace, with one major […]

The SMA and DMD Therapeutic Landscape

Patients with spinal muscular atrophy (SMA) stand to benefit from recent improvements in the current landscape of SMA treatment. Newborn screening is becoming more widely available, and with it, we can expect earlier diagnosis and access to treatment to slow progression of the condition. Zolgensma (onasemnogene abeparvovec-xioi), a gene-replacement therapy for SMA in pediatric patients, […]

Prostate Cancer Therapy: Insights into the Potential Role of PARP Inhibitors

This article is adapted from a teleconference that took place on January 27, 2020, and reflects the state of PARP at that time. A new teleconference that will update this data is scheduled for May 28, 2020. The clinical approach to prostate cancer has not yet been largely defined by patients’ genetics. However, poly (ADP-ribose) […]

COVID-19 May Have Blurred the Ophthalmology Sector, but Recovery Is a Few Blinks Away

The year 2020 started off very strong for ophthalmology, both in terms of same-store growth and with continued M&A activity. Then, as is true for nearly everything, COVID-19 changed it all. The American Academy of Ophthalmology on March 18 issued guidance strongly urging the discontinuation of all but the most urgent treatments – meaning only […]

COVID-19 and Public Perception

COVID-19 has fundamentally changed the way we live. It will continue to do so for the foreseeable future, impacting every part of our lives from the way we work to our recreation and pastimes. While today’s simple day-to-day life seems fraught with concern, GLG sought to capture a quantifiable snapshot of public perception of the […]

A Quick Take on STAT’s Remdesivir April 16 Reporting

Last week, STAT News reported that a clinical trial treating severe COVID-19 patients with Gilead Sciences’ antiviral medicine, remdesivir, at University of Chicago Medicine was performing well. In the article. Dr. Kathleen Mullane, the infectious disease physician running the trial, said, “The best news is that most of our patients have already been discharged, which […]

Speaker Biographies

Hilary Malone PhD, has over 25 years of experience in global drug development, regulatory &government affairs, manufacturing and commercialization within the biopharma industry. Hilary hassignificant board level and executive committee experience including large scale organizationalrestructuring/transformation/integration, major M&A, biotech start-up, capital raising, investorrelations and pre-IPO.​

Hilary is currently CEO of Stylus Medicine, a private genetic medicine biotech company. Previously sheserved as CEO of a Series-A neuroscience company. Prior to these roles, Hilary served as COO & EVP atValo Health Inc., Chief Regulatory Officer & SVP at Sanofi Inc., and Chief Regulatory Officer & SVP atPfizer and Wyeth. Previous experience also includes senior regulatory and drug development roles atReata Pharmaceuticals Inc., AstraZeneca plc and GlaxoSmithKline plc.​

Hilary also serves on the Board of Directors of Hansa Biopharma and Adthera Bio. Hilary holds a PhD inMolecular Neuropharmacology and a BSc in Physiology.

Dr. Thomas Lönngren is Director at his own company PharmaExec Consulting AB. He is the Chairman of the Board of directors at Egetis Therapeutics AB, Sweden. Dr Lönngren also serves as board member at Compass Pathways PLC, London UK and NDA Group, Sweden. He acts as advisor to the following companies and organizations: NDA group, Sweden, Sweden, Artis Venture, San Francisco, US, Fujimoto Japan, Skin2Neuron Pty Ltd, Sydney, Australia, US, Special advisor to the Centre for Innovation in Regulatory Science (CIRS), London UK. From 2001 until2011, Mr.Lönngren served as the Executive Director of the European Medical Agency. He was previously Deputy General Director of the Swedish Medical Product Agency until 2000. He has a degree in pharmacy and MSc in Social and Regulatory Pharmacy from Uppsala University. He is also an Honorary Member of the Royal Pharmaceutical Society of Great Britain, Honorary Fellow of the Royal College of Physicians in Great Britain, Honorary Doctorate from the University of Uppsala, Honorary Doctorate from University of Bath, UK.

Speaker Biographies

Marie-Anne Aymerich

Marie-Anne has built a portfolio of senior advisory and non-executive roles, following a successful international career in the FMCG and Luxury sectors. She is a non-executive director of Haleon, a FTSE100 company listed in 2022 after the demerger from GSK. She is also chairwoman of Haleon Environment and Societal Sustainability committee. She is the executive director of the Pierre Fabre Group where she also sits on the Strategic Committee, and she is a Board Member of The Academy of St. Martin-in-the-Fields, one of the world’s most prestigious chamber orchestras. She is also an angel investor and focuses her time and investments on start-ups with the strongest purpose and impact.

Marie-Anne is also a regular lecturer at HEC Paris on purposeful leadership, and she has created a serious game called “Planet Purpose” to upskill people on sustainability and purpose. Throughout her 35year executive career she delivered a strong track-record of business performance and growth in brands and portfolio in both developed and emerging economies.

As a senior leader with Unilever, she led a number of different personal care categories across France, Spain and the USA – including managing the Dove brand worldwide and culminating in leading Unilever’s global Oral Care division. She also worked for LVMH as Brand General Manager of Dior Perfumes and Cosmetics worldwide. Marie-Anne was also Vice-President of Imagine for Margo – Children with Cancer for ten years, a charity she helped found in 2011 with the goal of eradicating children’s cancer. The charity is the #1 charity focused on child cancer in France and has fundraised more than €14m since its creation. Marie-Anne is a graduate from HEC Paris. She is married and has two children aged 29 and 26.

Patrick Jephson

Patrick Jephson is a consultant, journalist, broadcaster and New York Times bestselling author, based in Washington D.C. He is a published authority on corporate and personal branding and crisis communications, addressing conferences worldwide as well as events at the U.S. State Department, the American University and the Annenberg School for Communication and Journalism.

With more than twenty-five years’ experience in the government, luxury and family office sectors, Patrick’s portfolio has included globally admired brands as well as national agencies and NGOs. He has also worked on reputation and legacy briefs with European, Middle Eastern and Asian families, including royalty. He now writes, presents, and advises on factual and drama TV programs, appearing on every major American and many international networks. He was recently an expert consultant to the award-winning Netflix series The Crown and provided live commentary on the Coronation of King Charles.

Patrick owes much of his practical communications and protocol experience to Princess Diana, who chose him to be her equerry and only private secretary/chief of staff. He served the Princess for eight years, responsible for all aspects of her public life, global humanitarian initiatives, and private organization. Having worked for an internationally high-profile woman (and as the father of two professionally successful daughters) he feels a special affinity for cross-cultural, gender and perception issues.

Patrick was born and raised in Ireland and holds a master’s degree in political science from Cambridge University. As an officer in the British Royal Navy, he served all over the world before being selected for royal duty. He is a citizen of the U.K., U.S.A., Ireland, and Canada.